
SENATE CONCURRENT RESOLUTION

REQUESTING THE AUDITOR TO ASSESS BOTH THE SOCIAL AND FINANCIAL
EFFECTS OF PROPOSED MANDATED HEALTH INSURANCE COVERAGE FOR
A PERCENTAGE OF THE COSTS OF INTRAVENOUS KETAMINE THERAPY
TO TREAT DEPRESSION.

1 WHEREAS, the State has a duty to protect and improve the
2 health and environment of the people; and

3
4 WHEREAS, a number of state residents suffer from various
5 mental health illnesses; and

6
7 WHEREAS, according to an article published in Current
8 Neuropharmacology, the use of ketamine is a valid antidepressant
9 option for the treatment of treatment-resistant depression and
10 has rapid antidepressant effects; and

11
12 WHEREAS, S.B. No. 967, Regular Session of 2025, proposes to
13 mandate insurance coverage for an unspecified percentage of the
14 costs of intravenous ketamine therapy to treat depression; and

15
16 WHEREAS, pursuant to section 23-51, Hawaii Revised
17 Statutes, before any legislative measure that mandates health
18 insurance coverage for specific health services, specific
19 diseases, or certain providers of health care services as part
20 of individual or group health insurance policies can be
21 considered, concurrent resolutions shall be passed requesting
22 the Auditor to prepare and submit to the Legislature a report
23 that assesses both the social and financial effects of the
24 proposed mandated coverage; now, therefore,

25
26 BE IT RESOLVED by the Senate of the Thirty-third
27 Legislature of the State of Hawaii, Regular Session of 2025, the
28 House of Representatives concurring, that the Auditor is
29 requested to assess, pursuant to section 23-51, Hawaii Revised
30 Statutes, both the social and financial effects of the proposed



1 mandated health insurance coverage under S.B. No. 967, Regular
2 Session of 2025, which proposes mandated insurance coverage for
3 a percentage of the costs of intravenous ketamine therapy to
4 treat depression; and
5

6 BE IT FURTHER RESOLVED that the Auditor is requested to
7 assess the proposed mandated insurance coverage for various
8 percentages of the costs of intravenous ketamine therapy to
9 treat depression in qualifying patients; and
10

11 BE IT FURTHER RESOLVED that the Auditor is requested to
12 submit a report of the Auditor's findings and recommendations,
13 including any proposed legislation, to the Legislature no later
14 than twenty days prior to the convening of the Regular Session
15 of 2026; and
16

17 BE IT FURTHER RESOLVED that certified copies of this
18 Concurrent Resolution be transmitted to the Auditor and
19 Insurance Commissioner.

